Featured Research

from universities, journals, and other organizations

Modulated Radiotherapy Can Cut Treatment Time For Cancer Of The Rectum Without Increasing Toxicity

Date:
June 16, 2008
Source:
Basque Research
Summary:
Application of modulated radiotherapy in the treatment of bowel cancer can enhance the results obtained by means of other conventional therapies. The technique has managed to apply the radiation in a way most adapted to the tumoral volume and risk areas, while minimizing irradiation to healthy tissue.

Application of modulated radiotherapy in the treatment of bowel cancer can enhance the results obtained by means of other conventional therapies. The technique has managed to apply the radiation in a way most adapted to the tumoral volume and risk areas, while minimising irradiation to healthy tissue. This radiotherapy procedure involves the administration of higher daily doses of radiation but with a total dose equivalent to conventional ones.

In this way the treatment time is cut by 30%, without a rise in side effects and with very high rates of pathological response.

These were the results of the study undertaken by a team of doctors at the University Hospital of Navarra, recently published in the specialist scientific journal, “International Journal of Radiation Oncology, Biology, Physics” of the American Society for Therapeutic Radiotherapy and Oncology. Involved in the research was a medical team from the area of digestive system tumours, led by Doctor José Javier Aristu, specialist at the Oncological Radiology Service. The article in the North American journal is the first published in the world giving clinical results from the application of preoperational modulated radiotherapy in tumours of the rectum.

Novelty for cancer of the rectum

IMRT (Intensity-Modulated Radiation Therapy) is a radiotherapy technique in which the administration of the radiation doses for the patient is effected by means of a lineal accelerator equipped with a system of multilaminas. Depending on the characteristics of the region that has to be irradiated, the planning system is capable of adapting high radiation doses to the shape of the target volume, enabling adjustments to be made to the morphology of the area to be treated in an individualized manner.

To date, the application of this procedure had been fundamentally limited to tumours located in the head, neck and prostrate gland. “This technique had been used in more confined tumours, more limited and smaller. We have now also begun to apply it to tumours of the rectum given that the conventional treatment, combining chemotherapy and radiotherapy, may cause high levels of toxicity”, explained Doctor Aristu.

The main goal in administering modulated radiotherapy in the treatment of cancer of the rectum, lies in excluding the greatest possible proportion of healthy tissue from the field of radiation, mainly the intestines, bladder and the healthy section of the rectum. We have shown that treatment using conventional radiotherapy and chemotherapy simultaneously causes about a 30% enteritis rate (inflammation of the intestine). However, in the study, we observed that the application of modulated radiotherapy reduces the rate of enteritis practically to the minimum in the patient who is being treated for bowel cancer. Moreover, on limiting the radiation to the tumoral mass and thus affecting healthy tissue less, it was possible to increase the daily dosage and cut the overall treatment time by approximately 30%, while the total dose administered is equivalent to two conventional treatments.

Study in phase I-II

This research, initially undertaken with 20 patients with cancer of the rectum, is in study phase I-II, the main purpose of which is to find the highest dose that can be applied using modulated radiotherapy in combination with chemotherapy. According to Doctor Aristu, the research showed for the first time that a radiation dose equivalent to that administered using conventional techniques can be applied using IMRT – in less time and with very promising rates of pathological response.


Story Source:

The above story is based on materials provided by Basque Research. Note: Materials may be edited for content and length.


Cite This Page:

Basque Research. "Modulated Radiotherapy Can Cut Treatment Time For Cancer Of The Rectum Without Increasing Toxicity." ScienceDaily. ScienceDaily, 16 June 2008. <www.sciencedaily.com/releases/2008/06/080616101126.htm>.
Basque Research. (2008, June 16). Modulated Radiotherapy Can Cut Treatment Time For Cancer Of The Rectum Without Increasing Toxicity. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/06/080616101126.htm
Basque Research. "Modulated Radiotherapy Can Cut Treatment Time For Cancer Of The Rectum Without Increasing Toxicity." ScienceDaily. www.sciencedaily.com/releases/2008/06/080616101126.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins